Five business-model myths that hold companies back

Linder, Jane C.; Cantrell, Susan

doi:10.1109/emr.2002.1032393

Cited by 12 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While earlier research has noted that firms may run multiple business models simultaneously (van der Meer, 2007;Chesbrough, 2006;Linder and Cantrell, 2001;Smith et al, 2010), the linking of corporate level concerns to individual business units and their business models has so far been sparse. Especially, extant literature lacks understanding of how corporate business models evolve and transform in multi-business unit organizations e an arena where we wish to contribute.…”

Section: Introductionmentioning

confidence: 99%

Corporate Business Model Transformation and Inter-Organizational Cognition: The Case of Nokia

Aspara

Lamberg

Laukia

et al. 2013

Long Range Planning

196

114

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Corporate Business Model Transformation and Inter-Organizational Cognition: The Case of Nokia

Aspara

Lamberg

Laukia

et al. 2013

Long Range Planning

196

114

View full text Add to dashboard Cite

“…Theoretically ideal strategies are grounded in reality, meaning that they are based on valid assumptions [15,39,44,51,59]. It does not matter how many of the other tests a strategy passes or how well constructed it may appear to be; if the strategy is based on flawed assumptions then it has lost touch with reality and, depending on the seriousness of the assumption, could lead to the business's demise.…”

Section: Strategy Based On Valid Assumptions?mentioning

confidence: 99%

“…The assumptions about the mission of the business involve assumptions about the goals of the organisation and what it considers to be meaningful results. The assumptions about the environment include assumptions about customers, their needs and behaviour [39]; assumptions about competitors and industry dynamics and trends; assumptions about society, markets, and technology; assumptions about the costs of running the business and revenues that will be generated [39]; and assumptions about the organisation's structure, its strengths and weaknesses [51]. Lastly, assumptions about core competencies involve assumptions about the skills and/or resources needed to accomplish the organisation's mission.…”

Section: Strategy Based On Valid Assumptions?mentioning

confidence: 99%

See 1 more Smart Citation

A Normative Model for Assessing Competitive Strategy

Ungerer

Cayzer

2016

SAJIE

View full text Add to dashboard Cite

The hyper-competitive nature of e-business has raised the need for a generic way to appraise the merit of a developed business strategy. Although progress has been made in the domain of strategy evaluation, the established literature differs over the 'tests' that a strategy must pass to be considered well-constructed. This paper therefore investigates the existing strategy-evaluation literature to propose a more integrated and comprehensive normative strategic assessment that can be used to evaluate and refine a business's competitive strategy, adding to its robustness and survivability. OPSOMMINGDie hiper-mededingende aard van e-besigheid het bygedra tot 'n groter behoefte vir 'n generiese manier om die meriete van 'n ontwikkelde besigheidstrategie te evalueer. Alhoewel daar alreeds vordering gemaak is in die strategie evaluering domein, wissel die bestaande literatuur beduidend in verband met die verskeie 'toetse' wat 'n strategie moet slaag om as 'goed' beskou te word. Hierdie artikel het daarom die bestaande strategie evaluering literatuur ondersoek en stel 'n meer geïntegreerde en omvattende normatiewe strategiese evaluering voor. Dié evaluering kan gebruik word om die kompeterende strategieë van besighede te evalueer en te verfyn, en dra daardeur by tot die besigheid se robuustheid en oorlewing.

show abstract

“…Based on Linder and Cantrell's work the BMs can be of three main types: the revenue model, profit model and cost structure (Linder et. al., 2000;Linder et. al., 2001).…”

mentioning

confidence: 99%

The science and business of novel therapeutics: the need for a complete picture

Malik¹

View full text Add to dashboard Cite

A unique characteristic of the biotechnology industry is its heavy reliance on continuous research & development (R&D). To explore the interdependence of science and commercialisation in the context of the biotechnology industry, this thesis built on expertise within the University of Queensland's Institute for Molecular Bioscience and the UQ Business School. It used a interdisciplinary approach, undertaking both (1) scientific discovery, in the area of disulfide-rich peptide based molecules with therapeutic potential, and (2) a longitudinal analysis of Business Model (BM) framework components, to better understand the research underpinning, and successful commercialisation of, novel therapeutics.Chapters 2 to 5 of the thesis describe research on naturally occurring cyclic (plant) and open -chain (Anuran) disulfide rich molecules, with serine protease inhibitory (primarily, trypsin) activity. MCoTI-II and SFTI-1 are ultra-stable cyclic peptides derived from plants seeds and are potent trypsin inhibitors. In Chapter 2, these peptides were studied for their inhibitory activity against another serine protease, matriptase. Matriptase is over-expressed in several carcinomas, and has been reported to play a role in cancer progression. Mutagenesis studies on MCoTI-II and SFTI-1 have provided insight into their structure-activity relationship, resulting in the design of the most potent matriptase inhibitor reported to date, with sub-nanomolar activity.In Chapter 3, open chain peptides, from frog skin secretions, with high sequence and structural similarity to SFTI-1, termed SFTI-1 like frog (SLF) peptides, were investigated. They have been reported to have both trypsin inhibitory and antimicrobial activity, which inspired us to further validate their antimicrobial properties in an animal model to treat Staphylococcal skin infection. Three SLF peptides (ORB, ORB2K and pYR) were found to have promising activity. Although cyclization of the SLF peptides was found to improve serum stability, it resulted in decreased efficacy against S. aureus. Nonetheless, this study opened doors to apply serine protease inhibitors to treat infections. Chapter 4 explored the used of related molecules in the inhibition of melanocortin (1 -5) receptors (MCR), which are recognised as drug targets because of their role in diseases such as inflammation, obesity and skin disease. Here, I showed that SFTI-1 had moderate activity against iii MCRs and, based on this result, I subsequently tested SLF peptides against MCR subtypes. Three novel SFL peptides (ORB, ORB2K and ranacyclin-T) exhibited promising antagonistic subtype selectivity.One of the limitations of peptides as drugs is high manufacturing costs, but their production in plants could potentially resolve this issue. Understanding the biosynthesis of MCoTI-II and SFTI-1 could facilitate the production of designer peptides in genetically modified plants. In Chapter 5, the biosynthesis of MCoTI-II was investigated. The enzyme, Asparaginyl endopeptidase (AEP) was found to play a cruc...

show abstract

Five business-model myths that hold companies back

Cited by 12 publications

References 0 publications

Corporate Business Model Transformation and Inter-Organizational Cognition: The Case of Nokia

Corporate Business Model Transformation and Inter-Organizational Cognition: The Case of Nokia

A Normative Model for Assessing Competitive Strategy

The science and business of novel therapeutics: the need for a complete picture

Contact Info

Product

Resources

About